Microbotox, a specific dilution of onabotulinum toxin A, is effective in treating mild-to-moderate acne vulgaris and erythematotelangiectatic rosacea, according to a new study.
Dupilumab and adjuvant tacrolimus improves severity of AD, new study shows
According to a new study, patients with atopic dermatitis (AD) are more likely to achieve mild disease severity when treated with dupilumab and adjuvant tacrolimus as opposed to dupilumab alone.
Inaugural Atopic Dermatitis Summit open for registration
Registration is open for the inaugural Atopic Dermatitis (AD) Summit. The virtual symposium will be held on Saturday, April 23, 2022, at 10:00 a.m. EDT.
Internalized skin bias negatively impacts QoL of HS patients
A new study has shown that internalized skin bias negatively impacts the mental health and quality of life (QoL) of patients with hidradenitis suppurativa (HS).
New study shows 1,064 nm lasers most effective for tattoo removal
A pre-clinical comparative study has shown that 1,064 nm lasers may be most effective in tattoo removal.
Difamilast ointment shows efficacy in treating atopic dermatitis
A new study found difamilast ointment 1% to be safe and efficacious in the treatment of atopic dermatitis (AD).
Psoriasis patients with and without psoriatic arthritis self-report higher analgesic use
According to a new study, psoriasis patients, with and without psoriatic arthritis (PsA), self-report using analgesics more than those without the disease. This may be due to increased joint pain.
Ustekinumab less effective for psoriasis in lower extremities, according to study
A new study has shown that clinical response in psoriasis patients treated with ustekinumab tends to vary by anatomical region, with the lower extremities seeing the least response.
Dupilumab-induced ocular surface disease more frequently associated with AD, study shows
According to a new study, dupilumab-induced ocular surface disease (DIOSD) appears to occur more frequently in patients with atopic dermatitis (AD) than in patients with other conditions being treated with the biologic.
University of Toronto establishes Chair in Ethnodermatology position
The University of Toronto has just established the AbbVie Chair in Ethnodermatology, one of the first positions of its kind, to support diversity in dermatology training, research and care, according to a press release.
HealthMinute.TV 